Vir Biotechnology
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: San Francisco, California, United States, North America
Region: California
Country: US
Continent: North America
About
Vir Biotechnology leverages the immune system to develop transformative medicines addressing infectious diseases and cancer. The company builds on next-generation antibody platforms and the PRO-XTEN masking technology to identify, optimize, and advance candidates from discovery to the clinic. Its focus includes chronic hepatitis delta and oncology programs, with a history of work in COVID-19 and Ebola, and a commitment to delivering meaningful patient outcomes from the United States and Europe.
Vir Biotechnology is a clinical-stage biopharmaceutical company that develops immunotherapies for infectious diseases and oncology. Leveraging its Next-Generation Antibody Platform and PRO-XTEN masking technology, the firm creates antibody-based treatments targeting conditions such as chronic hepatitis B and delta, HIV, and cancer. The company operates primarily in the United States and Europe.
Vir Biotechnology, Inc.
2016
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Grant
756400000
50m-100m
ipo
NASDAQ:VIR
nasdaq
Investors
Founders
Klaus Frueh
Louis Picker
Robert Nelsen
Leadership
Jason O’Byrne — Executive Vice President and Chief Financial Officer
Steven Rice — Chief Administrative Officer
Carrie Nodgaard — Sr. Director, Global Alliances & Program Team Lead
Lynne Krummen — SVP, Regulatory
Johanna Friedl-Naderer — EVP & Chief Business Officer, Global
Technology Stack
Products
Tobevibart and Elebsiran Combination Therapy for Chronic Hepatitis Delta: An investigational combination therapy using a monoclonal antibody and siRNA to target and suppress chronic hepatitis delta virus.
PRO-XTEN™ Masked T-cell Engagers for Oncology: Investigational T-cell engager therapies using PRO-XTEN™ masking technology to target tumor-specific antigens in cancer treatment.
Broadly Neutralizing Antibodies for HIV Cure Research: Investigational antibodies modified to enhance immune response aiming to neutralize diverse HIV strains and support cure efforts.
Tobevibart and Elebsiran Combination Therapy for Chronic Hepatitis B: An investigational combination therapy using antivirals and immunomodulators to improve functional cure rates in chronic hepatitis B patients.
VIR-2981 Monoclonal Antibody for Influenza: An investigational monoclonal antibody targeting influenza A and B strains to reduce medically attended influenza illness, especially in high-risk populations.
Sotrovimab for COVID-19 Treatment: A monoclonal antibody treatment developed for COVID-19 to engage the immune system and reduce disease severity.
Funding rounds
Post Ipo Equity · $150M · (2026-02-25)
Post Ipo Equity · $75M · (2026-02-23) · Lead: Astellas Pharma
Grant · $20M · (2026-02-23) · Lead: Astellas Pharma